Related Experiment Video
Updated: Aug 14, 2026

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing
Published on: October 16, 2018
Determinants of HIV drug resistance mutations in plasma virus after treatment interruption
Daniella Chilton1, Samir Dervisevic, Deenan Pillay
1Mortimer Market Centre, Camden Primary Care Trust, London, UK.
Abstract:
This study examines the utility of resistance testing during treatment interruption, making comparisons with the current IAS guidelines. A total of 188/1279 tests (14%) were performed during treatment interruption; 69/188 tests (36.7%) demonstrated key mutations. Time off therapy and the total number of previous drugs were both significantly associated with the presence of mutations. We conclude that resistance testing is of value up to 3 months after treatment interruption, and may convey some benefit up to 12 months.
Related Concept Videos
Retrovirus Life Cycles
Viral Mutations
Inhibitors of Virion Maturation and Assembly
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antiviral Nucleoside Inhibitors
Size and Structure of Viral Genomes

